Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3573

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3573
---
 we
    are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that
    such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled
    to indemnification;

127

    ●
    we
    are be obligated by our organizational documents to indemnify a person with respect to proceedings initiated by that person against
    us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right
    to indemnification; and

    ●
    the
    rights conferred in the Amended Certificate and the Company’s bylaws are not exclusive, and we are authorized to enter into
    indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.

If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.

The
trading market for our common stock and warrants is influenced by the research and reports that industry or securities analysts may publish
about us, our business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on
us. If no securities or industry analysts commence coverage of us, our share price and trading volume would likely be negatively impacted.
If any of the analysts who may cover us change their recommendation regarding our common stock or warrants adversely or provide more
favorable relative recommendations about our competitors, the price of shares of our common stock and warrants would likely decline.
If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on it, our common stock and warrants
could lose visibility in the financial markets, which in turn could cause the price or trading volume of our common stock and warrants
to decline.

Future
issuances of debt securities and equity securities may adversely affect us, including the market price of our common stock and warrants
and may be dilutive to existing stockholders.

In
the future, we may incur debt or issue equity-ranking senior to our common stock. Those securities will generally have priority upon
liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting our operating
flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and